Creative Medical Technology Holdings, Inc. announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals. This therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.

This medicine approach, focusing on a single high-risk patient, demonstrates the company's dedication to innovative, tailored healthcare solutions. CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a T1D precursor, at the cellular level. It embodies hope for high-risk individuals, offering a proactive defense against T1D development.

This aligns with the company's ethos of addressing diseases before they manifest, leveraging cutting-edge science for preventative care.